Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Relapse Prevention Study in Patients With Schizophrenia (REPRIEVE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vanda Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01291511
First received: February 3, 2011
Last updated: June 10, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)